BR9808515A - Tratamento ou profilaxia de câncer de próstata e hiperplasia benigna da próstata com moduladores de receptores de estrogênio seletivos - Google Patents
Tratamento ou profilaxia de câncer de próstata e hiperplasia benigna da próstata com moduladores de receptores de estrogênio seletivosInfo
- Publication number
- BR9808515A BR9808515A BR9808515-8A BR9808515A BR9808515A BR 9808515 A BR9808515 A BR 9808515A BR 9808515 A BR9808515 A BR 9808515A BR 9808515 A BR9808515 A BR 9808515A
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- prophylaxis
- prostate cancer
- selective estrogen
- receptor modulators
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title abstract 4
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 title abstract 3
- 206010060862 Prostate cancer Diseases 0.000 title abstract 3
- 208000000236 Prostatic Neoplasms Diseases 0.000 title abstract 3
- 238000011321 prophylaxis Methods 0.000 title abstract 3
- 208000004403 Prostatic Hyperplasia Diseases 0.000 title abstract 2
- 239000000333 selective estrogen receptor modulator Substances 0.000 title abstract 2
- 229940095743 selective estrogen receptor modulator Drugs 0.000 title abstract 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 abstract 3
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 abstract 2
- PXHHIBMOFPCBJQ-UHFFFAOYSA-N 1,2-dimethylpyrrolidine Chemical compound CC1CCCN1C PXHHIBMOFPCBJQ-UHFFFAOYSA-N 0.000 abstract 1
- AVFZOVWCLRSYKC-UHFFFAOYSA-N 1-methylpyrrolidine Chemical compound CN1CCCC1 AVFZOVWCLRSYKC-UHFFFAOYSA-N 0.000 abstract 1
- AHVYPIQETPWLSZ-UHFFFAOYSA-N N-methyl-pyrrolidine Natural products CN1CC=CC1 AHVYPIQETPWLSZ-UHFFFAOYSA-N 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 102000015694 estrogen receptors Human genes 0.000 abstract 1
- 108010038795 estrogen receptors Proteins 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- -1 hexamethyleneimino ring Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US4322397P | 1997-04-09 | 1997-04-09 | |
| PCT/US1998/007274 WO1998045288A1 (en) | 1997-04-09 | 1998-04-07 | Treatment or prophylaxis of prostatic cancer and benign prostatic hyperplasia with selective estrogen receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9808515A true BR9808515A (pt) | 2001-06-19 |
Family
ID=21926126
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9808515-8A BR9808515A (pt) | 1997-04-09 | 1998-04-07 | Tratamento ou profilaxia de câncer de próstata e hiperplasia benigna da próstata com moduladores de receptores de estrogênio seletivos |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP0975629A4 (no) |
| JP (1) | JP2001518900A (no) |
| KR (1) | KR20010006218A (no) |
| CN (1) | CN1259944A (no) |
| AU (1) | AU6966198A (no) |
| BR (1) | BR9808515A (no) |
| CA (1) | CA2286204A1 (no) |
| EA (1) | EA199900914A1 (no) |
| HU (1) | HUP0003589A3 (no) |
| ID (1) | ID24358A (no) |
| IL (1) | IL132277A0 (no) |
| NO (1) | NO994903L (no) |
| PL (1) | PL336205A1 (no) |
| TR (1) | TR199902701T2 (no) |
| WO (1) | WO1998045288A1 (no) |
| ZA (1) | ZA982819B (no) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6413533B1 (en) * | 1998-05-07 | 2002-07-02 | The University Of Tennessee Research Corporation | Method for chemoprevention of prostate cancer |
| US6610706B1 (en) | 1999-07-29 | 2003-08-26 | Eli Lilly And Company | Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b]thiophene hydrochloride |
| US6653479B1 (en) | 1999-07-29 | 2003-11-25 | Eli Lilly And Company | Crystalline form of 6-hydroxy-3-(4-[2-(piperidin-1-yl)ethoxy]phenoxy)-2-(4-methoxyphenyl)benzo[b] thiophene hydrochloride |
| EP1392304A1 (en) * | 2001-05-10 | 2004-03-03 | Cedars Sinai Medical Center | Use of benzothiophenes to treat and prevent prostate cancer |
| US7425565B2 (en) * | 2002-05-09 | 2008-09-16 | Cedars-Sinai Medical Center | Use of benzothiopenes to treat and prevent prostate cancer |
| RU2261716C1 (ru) * | 2004-02-24 | 2005-10-10 | Долженков Сергей Дмитриевич | Способ профилактики гнойно-воспалительных осложнений у больных доброкачественной гиперплазией простаты в послеоперационном периоде |
| JP5123935B2 (ja) * | 2006-05-22 | 2013-01-23 | ホルモス メディカル リミテッド | 選択的エストロゲン受容体モジュレーターまたはアロマターゼ阻害剤を用いた慢性非細菌性前立腺炎の治療方法 |
| JP5558358B2 (ja) | 2007-10-16 | 2014-07-23 | レプロス セラピューティクス インコーポレイティド | メタボリック症候群用のｔｒａｎｓ−クロミフェン |
| JP2015508825A (ja) | 2012-02-29 | 2015-03-23 | レプロス セラピューティクス インコーポレイティド | アンドロゲン欠乏症を治療するための併用療法 |
| CA2899030C (en) | 2013-02-19 | 2021-03-09 | Novartis Ag | Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders |
| AU2016352592B2 (en) | 2015-11-10 | 2023-04-27 | Paracrine Therapeutics Ab | Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and an anti estrogen |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5429922A (en) * | 1988-03-09 | 1995-07-04 | The Board Of Trustees Of The Leland Stanford Junior University | Composition and method for distinguishing virulent and non-virulent toxoplasma infections |
| US5510357A (en) * | 1995-02-28 | 1996-04-23 | Eli Lilly And Company | Benzothiophene compounds as anti-estrogenic agents |
| SG64896A1 (en) * | 1995-02-28 | 1999-05-25 | Lilly Co Eli | Benzothiophene compounds intermediates compositions and methods |
| US5731342A (en) * | 1996-02-22 | 1998-03-24 | Eli Lilly And Company | Benzothiophenes, formulations containing same, and methods |
-
1998
- 1998-04-02 ZA ZA9802819A patent/ZA982819B/xx unknown
- 1998-04-07 PL PL98336205A patent/PL336205A1/xx unknown
- 1998-04-07 ID IDW991188A patent/ID24358A/id unknown
- 1998-04-07 WO PCT/US1998/007274 patent/WO1998045288A1/en not_active Ceased
- 1998-04-07 AU AU69661/98A patent/AU6966198A/en not_active Abandoned
- 1998-04-07 HU HU0003589A patent/HUP0003589A3/hu unknown
- 1998-04-07 CA CA002286204A patent/CA2286204A1/en not_active Abandoned
- 1998-04-07 BR BR9808515-8A patent/BR9808515A/pt not_active Application Discontinuation
- 1998-04-07 CN CN98805956A patent/CN1259944A/zh active Pending
- 1998-04-07 EA EA199900914A patent/EA199900914A1/ru unknown
- 1998-04-07 TR TR1999/02701T patent/TR199902701T2/xx unknown
- 1998-04-07 IL IL13227798A patent/IL132277A0/xx unknown
- 1998-04-07 KR KR1019997009298A patent/KR20010006218A/ko not_active Withdrawn
- 1998-04-07 EP EP98915488A patent/EP0975629A4/en not_active Withdrawn
- 1998-04-07 JP JP54316898A patent/JP2001518900A/ja active Pending
-
1999
- 1999-10-08 NO NO994903A patent/NO994903L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0975629A4 (en) | 2001-03-21 |
| CN1259944A (zh) | 2000-07-12 |
| WO1998045288A1 (en) | 1998-10-15 |
| ZA982819B (en) | 1999-10-04 |
| HUP0003589A3 (en) | 2002-02-28 |
| JP2001518900A (ja) | 2001-10-16 |
| EP0975629A1 (en) | 2000-02-02 |
| HUP0003589A2 (hu) | 2002-01-28 |
| IL132277A0 (en) | 2001-03-19 |
| EA199900914A1 (ru) | 2000-04-24 |
| PL336205A1 (en) | 2000-06-05 |
| NO994903D0 (no) | 1999-10-08 |
| AU6966198A (en) | 1998-10-30 |
| CA2286204A1 (en) | 1998-10-15 |
| ID24358A (id) | 2000-07-13 |
| TR199902701T2 (xx) | 2000-02-21 |
| KR20010006218A (ko) | 2001-01-26 |
| NO994903L (no) | 1999-12-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9809389A (pt) | Tratamento de distúrbios do sistema nervoso central com modulados de receptores de estrogênio seletivos | |
| EA200000220A1 (ru) | Сочетание ингибитора тирозинкиназы и химической стерилизации для лечения рака предстательной железы | |
| AU6613896A (en) | Chemical compounds | |
| TR199801195T2 (xx) | Tedavide yararl� kinolin ve kinozilin bile�ikleri. | |
| AU674477B2 (en) | Heterocyclic-cyclic amine derivatives | |
| BR9808515A (pt) | Tratamento ou profilaxia de câncer de próstata e hiperplasia benigna da próstata com moduladores de receptores de estrogênio seletivos | |
| KR100263496B1 (ko) | 탁솔 유도체 및 이의 제조방법 | |
| GB9929552D0 (en) | Compounds | |
| YU48698A (sh) | Karboksamidni derivati pirolidina, piperidina i heksahidroazepina za lečenje oboljenja na bazi tromboze | |
| KR20000005379A (en) | Isatin derivatives as acetylcholinesterase inhibitors and analgesics | |
| AUPR118000A0 (en) | Therapeutic molecules and methods | |
| GB9727521D0 (en) | Substituted 2-benzylamino-2-phenyl-acetamide compounds | |
| PL341050A1 (en) | Heterocyclic cytoxic agents | |
| TR200001288T2 (tr) | Östrojen yoksunluğu sendromunun tedavisinde faydalı 2-arilbenzo (b) tiyofenler. | |
| PT1189923E (pt) | Derivados aromaticos e heterociclicos de fitosterois e/ ou fitostanois para utilizacao no tratamento ou prevencao de doenca cardiovascular | |
| AU2393997A (en) | Alpha1-adrenergic receptor antagonists | |
| EA199900910A1 (ru) | Профилактика рака молочной железы селективными модуляторами рецепторов эстрогена | |
| ATE181324T1 (de) | Im kardiovaskulären system aktive seco-d-steroide und diese enthaltende pharmazeutische zubereitungen | |
| YU46302A (sh) | Supstituisani piroli | |
| NZ337048A (en) | Use of N-[1-methyl-(substituted phenyl)ethyl]-3-oxo-4-aza-5alpha-androst-1-ene-17beta-carboxamide derivatives to treat prostate cancer | |
| DK0771201T3 (da) | Anvendelse af 2-phenyl-3-aroylbenzothiophener til fremstilling af et medikament til inhibering af primær endometrisk hyperplasi | |
| EP0551952A3 (en) | 17-aryl-substituted steroidal compounds active on the cardiovascular system | |
| DE69705772D1 (de) | Adamantyl substituierte Oxindole als pharmazeutische Wirkstoffe | |
| MX9603797A (es) | Agentes terapeuticos para su uso en la terapia del cancer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA10 | Dismissal: dismissal - article 33 of industrial property law | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |